MedPath

To determine the effects of investigational product for the treatment of ADHD in children and teens.

Phase 2
Conditions
Health Condition 1: F900- Attention-deficit hyperactivity disorder, predominantly inattentive type
Registration Number
CTRI/2019/09/021110
Lead Sponsor
atural Remedies Private Limited
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1. Children/ adolescent of both sexes between 6 years to 16 years old who exhibit mild to moderate ADHD with predominantly inattentive or combined presentation according to DSM V criteria.

2.Inattentive subset and hyperactivity subset of not greater than 23 on SNAP IV scale.

3. Voluntary assent to participate in the study from all whose are more then 7 years of age.

4. Informed Consent signed by legal guardian/research participant when possible.

5. Results of lab tests(chemistry, blood count and urine), physical examination and vital parameters with no clinically significant changes.

Exclusion Criteria

1. WISC-IV-SF, subjects whose score are less than 80.

2.Research participants with known hypersensitivity to the other medication. History of alcohol or drug abuse by research participant.

3. Where the immediate concern is around another primary psychiatric diagnosis other than ADHD.

4. Diagnosis of psychiatric comorbidities, except for simple phobia, adjustment disorders, learning disorders, oppositional defiant disorder and sleep disorders.

5. History of seizures(except for mild febrile seizures) within 2 years from the time of recruitment.

6. Diagnosis of Tourette Syndrome and chronic tics.

7. Research participants who are making use of drugs for the treatment of ADHD in last three months.

8. Research participants who are making use of anticonvulsants, antidepressants and anti psychotics upto 6 weeks prior to study entry.

9. Positive beta HCG test for girls who have attained menarchy.

10. Patient at identified risk of suicide through clinical interview.

11. Children/ adolescents with ADHD predominantly hyperactive/impulsive.

12. Other conditions considered by the investigator as reasonable for the disqualification of the subject,s participation in the study.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
ADHD symptoms as measured by the SNAP-IV andCGI-I Scale scores.Timepoint: 6 months
Secondary Outcome Measures
NameTimeMethod
1. Computer-based Continuous Performance Test scores and Rey Auditory Verbal Learning Test (RAVLT) scores. <br/ ><br>2. SafetyTimepoint: 1. on week 0, 14 and 28 <br/ ><br>2. on week 0 and 28
© Copyright 2025. All Rights Reserved by MedPath